2 Iconography
Access to the text (HTML) Access to the text (HTML)
PDF Access to the PDF text

Access to the full text of this article requires a subscription.
  • If you are a subscriber, please sign in 'My Account' at the top right of the screen.

  • If you want to subscribe to this journal, see our rates

Journal of the American Academy of Dermatology
Volume 57, n° 4
pages 581-587 (octobre 2007)
Doi : 10.1016/j.jaad.2007.04.001
accepted : 10 April 2007

The PASE questionnaire: Pilot-testing a Psoriatic Arthritis Screening and Evaluation tool

M. Elaine Husni, MD, MPH a, Kathryn H. Meyer, MS b, Darel S. Cohen, MD, MPH c, Elinor Mody, MD d, e, Abrar A. Qureshi, MD, MPH c, e,
a Departments of Rheumatic and Immunologic Diseases, Cleveland Clinic Foundation, Cleveland, Ohio 
b Department of Quantitative Health Sciences, Cleveland Clinic Foundation, Cleveland, Ohio 
c Department of Dermatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 
d Division of Allergy, Immunology and Rheumatology, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 
e Center for Skin and Related Musculoskeletal Diseases, Brigham and Women’s Hospital, Harvard Medical School, Boston, Massachusetts 

Reprint requests: Abrar A. Qureshi, MD, MPH, Assistant Professor, Harvard Medical School, Department of Dermatology, Brigham and Women’s Hospital, 45 Francis St, 221L, Boston, MA 02115.

Complications associated with psoriatic arthritis (PsA) may be prevented with early diagnosis and initiation of therapy. Up to one third of psoriasis patients may have PsA. There is a need to screen psoriasis patients early for symptoms of PsA.


To develop and validate a patient self-administered tool to screen psoriasis patients for signs and symptoms of inflammatory arthritis.


The questionnaire (PASE; P soriatic A rthritis S creening and E valuation) was developed using standardized methodology for the development of both functional and health-related instruments geared toward musculoskeletal diseases. A multidisciplinary team of dermatologists, rheumatologists, and patient focus groups were involved in the design of the questionnaire.


A total of 69 participants with known psoriasis and PsA before the initiation of systemic therapy were screened with PASE after institutional review board approval. The average age was 51 years, and 51% of the participants were female. A total of 25% (17/69) were diagnosed with PsA in this study, and 37% (24/69) were diagnosed with osteoarthritis. Patients with concomitant PsA and osteoarthritis were excluded. PASE total scores ranged from 23 to 68 (possible range, 15-75). In patients with PsA, the median total score was 53 (25th and 75th percentiles, 49 and 63, respectively) and 39 (25th and 75th percentiles, 28 and 47) in non-PsA patients (P < .001). Median PASE total score for osteoarthritis patients was 43 (25th and 75th percentiles, 37 and 51) and significantly different to PsA patient total median scores (P = .002). Using receiver operator curves, we determined that PASE total score ≥47 was able to distinguish PsA from non-PsA patients with 82% sensitivity and 73% specificity.


PASE is a screening tool for PsA and does not replace a comprehensive musculoskeletal evaluation by a rheumatologist.


The PASE questionnaire is a self-administered tool that can be used to screen for PsA among patients with psoriasis. PASE can distinguish between symptoms of PsA and osteoarthritis. A larger study is needed to validate PASE in dermatology clinics in the community.

The full text of this article is available in PDF format.

 Supported by a grant from the Department of Dermatology, Brigham and Women’s Hospital (to A. A. Q.).
 Disclosure: Dr Qureshi is a consultant for and has spoken for Abbott, Amgen, and Genentech, and has had a limited consulting relationship with Centocor. Dr Mody is a speaker for Abbott, Amgen, and Genentech. Dr Husni is a consultant for Genentech and Amgen. Ms Meyer and Dr Cohen have no conflicts of interest to declare.

© 2007  American Academy of Dermatology, Inc.@@#104156@@
EM-CONSULTE.COM is registrered at the CNIL, déclaration n° 1286925.
As per the Law relating to information storage and personal integrity, you have the right to oppose (art 26 of that law), access (art 34 of that law) and rectify (art 36 of that law) your personal data. You may thus request that your data, should it be inaccurate, incomplete, unclear, outdated, not be used or stored, be corrected, clarified, updated or deleted.
Personal information regarding our website's visitors, including their identity, is confidential.
The owners of this website hereby guarantee to respect the legal confidentiality conditions, applicable in France, and not to disclose this data to third parties.
Article Outline
You can move this window by clicking on the headline